Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 160

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 160
---
     | $               |      - |
| Forfeited and cancelled                             |     |           |   (48,426 | ) |     | $                |  4.34 |     |             |   - |     | $               |      - |
| Outstanding as of December 31, 2023                 |     |           | 2,050,197 |   |     | $                | 10.90 |     |             | 7.9 |     | $               | 36,363 |
| Exercisable as of December 31, 2023                 |     |           | 1,184,749 |   |     | $                | 15.59 |     |             | 7.4 |     | $               |      - |
| Vested and expected to vest as of December 31, 2023 |     |           | 2,050,197 |   |     | $                | 10.90 |     |             | 7.9 |     | $               | 36,363 |

The following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods presented:

SCHEDULE OF STOCK BASED COMPENSATION EXPENSES

|                                        |     | For the year ended December 31, 
 2023                            |      2023 |     | 2022 |      2022 |
|:---------------------------------------|:----|:--------------------------------|----------:|:----|:-----|----------:|
| Research and development               |     | $                               |   792,273 |     | $    |   709,527 |
| General and administrative             |     |                                 | 2,173,665 |     |      | 2,247,722 |
| Total stock-based compensation expense |     | $                               | 2,965,938 |     | $    | 2,957,249 |

As of December 31, 2023, total compensation cost not yet recognized related to unvested stock options was approximately $ 2.2million, which is expected to be recognized over a weighted-average period of approximately 0.7years.

The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted average inputs used to measure